Literature DB >> 1361132

Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose.

N W Spurling1, P F Carey.   

Abstract

1. A three-stage protocol is described for a dose-ranging study which defines the maximum repeatable dose (MRD) and provides a preview of the toxicology of new, pharmacologically active, substances before commencing the first formal regulatory toxicity studies, usually of 2 or 4 weeks duration. 2. Additionally, a range of toxicokinetic (TK) data relevant to protocol design for formal studies is generated. 3. Stage A is a dose incrementation process in which the MRD is provisionally determined and basic TK values generated. 4. In stage B the animals are dosed daily for at least 7 d, the MRD is substantiated and a wider range of TK data obtained. 5. In stage C, each of the dose levels identified for a formal study is administered once to investigate the relationship of doses to TK data. 6. This protocol can be completed using as few as 24 rats or six dogs (or primates). 7. Selection of dose levels for the first formal studies can be greatly aided by the results of a well-designed dose-ranging study including TK data. 8. For particularly toxic substances, the findings of studies based on this protocol have frequently been sufficiently clear to warrant early termination of their development.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361132     DOI: 10.1177/096032719201100603

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  1 in total

1.  Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine.

Authors:  Seth Kwabena Amponsah; Benoit Banga N'guessan; Martin Akandawen; Abigail Aning; Sedem Yawa Agboli; Eunice Ampem Danso; Kwabena Frimpong-Manso Opuni; Isaac Julius Asiedu-Gyekye; Regina Appiah-Opong
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.